Browsing Tag
pharma M&A
4 posts
Biocon goes all-in on biosimilars with $5.5bn Biocon Biologics merger and Viatris exit
Biocon to merge Biocon Biologics in $5.5B deal with full ownership via share swap and cash. Find out what it means for investors and global biosimilar strategy.
Can Lilly’s milestone-heavy deal for Adverum reshape how Big Pharma acquires gene therapy platforms?
Lilly’s $12.47-per-share buyout of Adverum Biotechnologies puts milestone CVRs at the center of biotech M&A. But can this deal model truly balance risk and reward?
Are short-acting psychedelics the next big bet in mental health? What pharma’s billion-dollar moves suggest
Are short-acting psychedelics the future of psychiatry? Pharma’s billion-dollar bets say yes. We explore what’s behind the new wave of scalable mental health drugs.
AbbVie completes $1.2bn acquisition of Gilgamesh’s bretisilocin: Is big pharma finally embracing psychedelic psychiatry?
AbbVie completes $1.2B acquisition of bretisilocin from Gilgamesh, betting big on short-acting psychiatric drugs. Here’s what the deal signals for depression care.